Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF
Journal of dual diagnosis · 39 citas
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Gazi Üniversitesi
- Gobierno
- National Institute of Mental Health
- Gobierno
- National Institute on Drug Abuse
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NIDA NIH HHS
- Gobierno
- NCATS NIH HHS
- Gobierno
- NIMH NIH HHS
- Subvenciones
- National Institute on Drug Abuse (K05DA031247); National Institute on Drug Abuse (1K05DA031247-01); National Institute of Mental Health (R33MH096858); National Center for Advancing Translational Sciences (UL1-TR001067); National Institute on Drug Abuse (R36DA036767); National Institute on Drug Abuse (1R36DA036767-01)
Según 7 financiadores declarados.
Publicación
- Publicado
- 2015-10-02 · J Dual Diagn · vol. 11 · número 3-4 · págs. 189–202
- Editorial
- Taylor & Francis
- Citado
- 49 citas · más que el 82% de estudios similares · 1.6× el promedio de su campo
- Referencias
- 102 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Muscle metabolism and nutrition · Advanced MRI Techniques and Applications · Nutrition and Health in Aging
- Palabras clave
- Phosphocreatine, Creatine Monohydrate, Methamphetamine, Creatine, Depression (economics), Hamd, Medicine, Internal medicine, Beck Depression Inventory, Anxiety, Psychiatry, Psychology, Placebo
- MeSH
- brain, humans, amphetamine-related disorders, creatine, methamphetamine, phosphocreatine, antidepressive agents, diagnosis, dual (psychiatry), treatment outcome, magnetic resonance spectroscopy, pilot projects, depressive disorder, adult, middle aged, female, young adult
10 autores
- Tracy Hellem🇺🇸 · autor de correspondenciaUniversity of Utah
- Young‐Hoon Sung🇺🇸University of Utah
- Xian-Feng Shi🇺🇸University of Utah
- Marjorie A. Pett🇺🇸University of Utah
- Gwen Latendresse🇺🇸University of Utah
- Jubel Morgan🇺🇸University of Utah
- Rebekah S. Huber🇺🇸University of Utah
- Danielle Kuykendall🇺🇸University of Utah
- Kelly J. Lundberg🇺🇸University of Utah
- Perry Franklin Renshaw🇺🇸Salt Lake Community College; University of Utah; VA Rocky Mountain Network; Mental Illness Research, Education and Clinical Centers
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Depression among methamphetamine users is more prevalent in females than males, but gender-specific treatment options for this comorbidity have not been described. Reduced brain phosphocreatine levels have been shown to be lower in female methamphetamine users compared to males, and, of relevance, studies have demonstrated an association between treatment-resistant depression and reduced brain phosphocreatine concentrations. The nutritional supplement creatine monohydrate has been reported to reduce symptoms of depression in female adolescents and adults taking antidepressants, as well as to increase brain phosphocreatine in healthy volunteers. Therefore, the purpose of this pilot study was to investigate creatine monohydrate as a treatment for depression in female methamphetamine users.
Methods
Fourteen females with depression and comorbid methamphetamine dependence were enrolled in an 8-week open label trial of 5 g of daily creatine monohydrate and of these 14, 11 females completed the study. Depression was measured using the Hamilton Depression Rating Scale (HAMD) and brain phosphocreatine levels were measured using phosphorus magnetic resonance spectroscopy pre- and post-creatine treatment. Secondary outcome measures included anxiety symptoms, measured with the Beck Anxiety Inventory (BAI), as well as methamphetamine use, monitored by twice weekly urine drug screens and self-reported use.
Results
The results of a linear mixed effects repeated measures model showed significantly reduced HAMD and BAI scores as early as week 2 when compared to baseline scores. This improvement was maintained through study completion. Brain phosphocreatine concentrations were higher at the second phosphorus magnetic resonance spectroscopy scan compared to the baseline scan; Mbaseline = 0.223 (SD = 0.013) vs. Mpost-treatment = 0.233 (SD = 0.009), t (9) = 2.905, p <.01, suggesting that creatine increased phosphocreatine levels. Also, a reduction in methamphetamine positive urine drug screens of greater than 50% was observed by week 6. Finally, creatine was well tolerated and adverse events that were related to gastrointestinal symptoms and muscle cramping were determined as possibly related to creatine.
Conclusions
The current study suggests that creatine treatment may be a promising therapeutic approach for females with depression and comorbid methamphetamine dependence. This study is registered on clinicaltrials.gov (NCT01514630).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.